JPMorgan assumed coverage of HCA Healthcare (HCA) with a Neutral rating and $380 price target The firm believes favorable trends across sales and expenses for managed care companies should allow for margin expansion in 2025, but considers the setup into 2026 to be more bearish, saying potential volume rollover and regulatory uncertainty following the November elections present an “imperfect storm” of payer mix headwinds and a negative overhang on go-forward sentiment for the hospitals.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Block, Five Below downgraded: Wall Street’s top analyst calls
- HCA Healthcare downgraded to Underweight from Equal Weight at Wells Fargo
- Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz
- HCA Healthcare downgraded to Market Perform from Outperform at Raymond James